Skip to main content
. 2021 Jul 29;6:93. Originally published 2021 Apr 29. [Version 2] doi: 10.12688/wellcomeopenres.16594.2

Table 4. Summary of RAS to any DAA in genotype 1a by time point.

Baseline Post-failure
Resistance to NS5a inhibitors N=13 N=18
24: K24R 1 (8%) 2 (11%)
28: M28T - 5 (28%)
      M28V 6 (46%) 5 (28%)
30: Q30H 1 (8%) -
      Q30L - 1 (6%)
      Q30R - 6 (33%)
31: L31M - 2 (11%)
58: H58D - 2 (11%)
93: Y93F 1 (8%) -
      Y93H - 1 (6%)
      Y93N 1 (8%) 1 (6%)
Resistance to NS5b inhibitors N=7 N=3
448: Y448H 2 (29%) -
556: S556G 5 (71%) 3 (100%)
Resistance to protease inhibitors N=30 N=14
36: V36M 1 (3%) 1 (7%)
55: V55A 3 (10%) 2 (14%)
      V55I 3 (10%) 1 (7%)
80: Q80K 21 (70%) 9 (64%)
      Q80L 1 (3%) -
155: R155K - 1 (7%)
168: D168A - 1 (7%)